Show simple item record

dc.contributor.authorBurri, Lenaeng
dc.contributor.authorBjørndal, Bodileng
dc.contributor.authorWergedahl, Hegeeng
dc.contributor.authorBerge, Kjetileng
dc.contributor.authorBohov, Pavoleng
dc.contributor.authorSvardal, Asbjørneng
dc.contributor.authorBerge, Rolf Kristianeng
dc.date.accessioned2011-11-21T15:40:59Z
dc.date.available2011-11-21T15:40:59Z
dc.date.issued2011-04-09eng
dc.identifier.citationLipids Volume 46(8): 679-689en
dc.identifier.issn0024-4201eng
dc.identifier.urihttp://hdl.handle.net/1956/5213
dc.description.abstractThe administration of tetradecylthioacetic acid (TTA), a hypolipidemic and anti-inflammatory modified bioactive fatty acid, has in several experiments based on high fat diets been shown to improve lipid transport and utilization. It was suggested that increased mitochondrial and peroxisomal fatty acid oxidation in the liver of Wistar rats results in reduced plasma triacylglycerol (TAG) levels. Here we assessed the potential of TTA to prevent tumor necrosis factor (TNF) a-induced lipid modifications in human TNFa (hTNFa) transgenic mice. These mice are characterized by reduced b-oxidation and changed fatty acid composition in the liver. The effect of dietary treatment with TTA on persistent, low-grade hTNFa overexpression in mice showed a beneficial effect through decreasing TAG plasma concentrations and positively affecting saturated and monounsaturated fatty acid proportions in the liver, leading to an increased anti-inflammatory fatty acid index in this group. We also observed an increase of mitochondrial b-oxidation in the livers of TTA treated mice. Concomitantly, there were enhanced plasma levels of carnitine, acetyl carnitine, propionyl carnitine, and octanoyl carnitine, no changed levels in trimethyllysine and palmitoyl carnitine, and a decreased level of the precursor for carnitine, called c-butyrobetaine. Nevertheless, TTA administration led to increased hepatic TAG levels that warrant further investigations to ascertain that TTA may be a promising candidate for use in the amelioration of inflammatory disorders characterized by changed lipid metabolism due to raised TNFa levels.en
dc.language.isoengeng
dc.publisherSpringereng
dc.rights.urihttp://www.springer.com/open+access/open+choice?SGWID=0-40359-0-0-0eng
dc.subjectTetradecylthioacetic acideng
dc.subjectDietary treatmenteng
dc.titleTetradecylthioacetic Acid Increases Hepatic Mitochondrial b-Oxidation and Alters Fatty Acid Composition in a Mouse Model of Chronic Inflammationeng
dc.typePeer reviewedeng
dc.typeJournal articleeng
dc.subject.nsiVDP::Medical disciplines: 700::Health sciences: 800::Nutrition: 811eng
dc.rights.holder©The Author(s) 2011
dc.type.versionpublishedVersioneng
bora.peerreviewedPeer reviewedeng
bibo.doihttp://dx.doi.org/10.1007/s11745-011-3536-2eng
dc.identifier.doi10.1007/s11745-011-3536-2


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record